EDITAS MEDICINE, INC. Revenue from Contract with Customer, Including Assessed Tax
EDITAS MEDICINE, INC. (EDIT) reported Revenue from Contract with Customer, Including Assessed Tax of $6.12 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-03-01
- EDITAS MEDICINE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $6.12M, a 66.87% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-09-30 was $14.52M, a 131.12% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-06-30 was $7.37M, a 138.04% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, including assessed tax for the quarter ending 2018-03-31 was $3.93M, a 475.81% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, including assessed tax for fiscal 2018 was $31.94M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $6.12M 10-K · filed 2019-03-01 | $20.64M derived: sum of 2 quarters · filed 2019-03-01 | $28.01M derived: sum of 3 quarters · filed 2019-03-01 | $31.94M 10-K · filed 2019-03-01 |
| 2018-09-30 | $14.52M 10-K · filed 2019-03-01 | $21.89M derived: sum of 2 quarters · filed 2019-03-01 | $25.82M 10-Q · filed 2018-11-08 | $29.48M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-06-30 | $7.37M 10-K · filed 2019-03-01 | $11.30M 10-Q · filed 2018-08-07 | $14.97M derived: sum of 3 quarters · filed 2019-03-01 | $21.25M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-03-31 | $3.93M 10-K · filed 2019-03-01 | $7.59M derived: sum of 2 quarters · filed 2019-03-01 | $13.88M derived: sum of 3 quarters · filed 2019-03-01 | $16.97M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-12-31 | $3.67M 10-K · filed 2019-03-01 | $9.95M derived: sum of 2 quarters · filed 2019-03-01 | $13.05M derived: sum of 3 quarters · filed 2019-03-01 | $13.73M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-09-30 | $6.28M 10-K · filed 2019-03-01 | $9.38M derived: sum of 2 quarters · filed 2019-03-01 | $10.06M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2017-06-30 | $3.10M 10-K · filed 2019-03-01 | $3.78M derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $682.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |